SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Panacea Biotec - Quaterly Results

13 Feb 2024 Evaluate
A decent increase of about 32.32% in the sales to Rs. 952.30 millions was observed for the quarter ended December 2023. The sales figure stood at Rs. 719.70 millions during the year-ago period.The company suffered a huge decline of -96.75% to Rs. 4.30  millions from Rs. 132.40 millions  of corresponding previous quarter.The company reported a degrowth in operating Profit to 96.90 millions from 220.00 millions.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202312 202212 % Var 202312 202212 % Var 202303 202203 % Var
Sales 952.30 719.70 32.32 2792.30 1820.50 53.38 2570.70 2355.00 9.16
Other Income 30.50 97.10 -68.59 85.20 241.60 -64.74 344.30 125.70 173.91
PBIDT 96.90 220.00 -55.95 319.30 -418.90 -176.22 -281.90 -601.10 -53.10
Interest 34.10 26.80 27.24 104.20 73.60 41.58 100.60 70.40 42.90
PBDT 62.80 193.20 -67.49 215.10 -492.50 -143.68 -382.50 -671.50 -43.04
Depreciation 52.10 60.80 -14.31 159.50 186.00 -14.25 245.00 264.30 -7.30
PBT 10.70 132.40 -91.92 55.60 -678.50 -108.19 -627.50 -935.80 -32.95
TAX 6.40 0.00 0.00 6.40 0.00 0.00 247.90 0.00 0.00
Deferred Tax 0.00 0.00 0.00 0.00 0.00 0.00 247.90 0.00 0.00
PAT 4.30 132.40 -96.75 49.20 -678.50 -107.25 -875.40 -935.80 -6.45
Equity 61.30 61.30 0.00 61.30 61.30 0.00 61.30 61.30 0.00
PBIDTM(%) 10.18 30.57 -66.71 11.44 -23.01 -149.70 -10.97 -25.52 -57.04

Panacea Biotec Share Price

342.05 -15.95 (-4.46%)
20-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1668.00
Dr. Reddys Lab 1232.25
Cipla 1228.90
Zydus Lifesciences 936.35
Lupin 2328.60
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×